The dates and venue for the upcoming Hematology event will be announced shortly.
For further details, Please contact us at secretary@magnusmeetings.com or call + 1 (702) 988 2320.
Any therapeutic substance obtained from human blood, including whole blood and other blood components for transfusion, as well as plasma-derived pharmaceutical compounds, is referred to as a blood product. Medicinal (medical therapeutic) products obtained from human blood and plasma donations play an important role in medical care. Every year, blood products that are safe, effective, and of high-quality help to improve and save millions of lives. Inadequate or unsafe blood supplies have a detrimental influence on the ability of critical health services and programmes to offer proper patient care in a variety of acute and chronic illnesses. Access to safe, effective, and quality-assured blood products for all patients who require transfusion is a critical component of a functional health system and essential for patient safety.
Title : Hereditary hemolytic anemias due to red blood cell membranopathies rheological and genetic approach
Joan Lluis Vives Corrons, Institute for Leukaemia Research Josep Carreras, Spain
Title : Histologic transformation of mantle zone lymphoma to diffuse large B-Cell lymphoma: A case report of disease relapse after Covid-19 infection
Lilija Bancevica, Riga Stradins University, Latvia
Title : Improving outcomes of curable lymphoma in resource constrained regions
Reena Nair, TATA Medical Centre, India
Title : Covid-19 and erythrocyte groups
Marina Nagervadze, Batumi Shota Rustaveli State University, Georgia
Title : Achieving 100% blood traceability compliance: A United Kingdom district hospital experience
Francis Ajeneye, Princess Alexandra Hospital NHS Trust, United Kingdom
Title : Role of erythrocytapheresis in sickle cell anemia crisis management: A tertiary care centre experience from Chhattisgarh state of central India
Neelesh Jain, Transfusion Medicine at Balco Medical Centre, India